Byetta exenatide: Additional Phase III data

Additional data from the National Heart, Lung and Blood Institute (NHLBI)-sponsored Phase III ACCORD trial in 10,251 Type II diabetics at high risk for heart attack and stroke showed that there was no difference in the rates of progression to kidney failure, major vision loss or advanced peripheral neuropathy between intensive glycemic therapy (target HbA1c <6%) and standard glycemic therapy (target HbA1c of 7-7.9%). However, patients receiving intensive glycemic therapy did have reduced incidence of albuminuria, fewer cataract surgeries and improved visual acuity and nerve function scores vs. standard glycemic therapy. Data were presented at the American Diabetes Association meeting in Orlando and published in The Lancet. ...